Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
The plant is scheduled to come on stream in September 2024
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Expanding US operations to address the increased demand for API development and manufacturing
Subscribe To Our Newsletter & Stay Updated
